Published in J Hepatol on September 01, 2005
Laser ablation for small hepatocellular carcinoma: State of the art and future perspectives. World J Hepatol (2014) 0.88
Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol (2013) 0.83
Percutaneous ultrasound-guided ablation of BW7756-hepatoma using ethanol or acetic acid in a rat model. BMC Gastroenterol (2007) 0.80
Effect of microbubble-enhanced ultrasound on percutaneous ethanol ablation of rat walker-256 tumour. Eur Radiol (2015) 0.75
Hepatocellular carcinoma. Lancet (2012) 18.09
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17
Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75
CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest (2009) 3.62
Focus on hepatocellular carcinoma. Cancer Cell (2004) 3.49
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Chemoembolization for hepatocellular carcinoma. Gastroenterology (2004) 2.89
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology (2004) 2.54
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol (2012) 2.53
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology (2006) 2.38
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer (2009) 2.38
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology (2013) 2.37
Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol (2008) 2.22
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
Major achievements in hepatocellular carcinoma. Lancet (2009) 2.10
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology (2009) 1.90
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86
MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology (2003) 1.85
Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol (2011) 1.84
The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist (2010) 1.84
Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology (2014) 1.78
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77
Staging systems in hepatocellular carcinoma. HPB (Oxford) (2005) 1.71
Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71
Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68
Characterization of focal liver lesions with contrast-enhanced ultrasound. Ultrasound Med Biol (2010) 1.67
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66
High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl (2004) 1.65
Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology (2004) 1.65
Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol (2010) 1.62
Experimental models of hepatocellular carcinoma. J Hepatol (2008) 1.61
Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol (2012) 1.57
Pulmonary radiofrequency ablation--an international study survey. Anticancer Res (2004) 1.54
Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol (2009) 1.52
New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res (2010) 1.46
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44
Targeting liver lesions for radiofrequency ablation: an experimental feasibility study using a CT-US fusion imaging system. Invest Radiol (2008) 1.40
Colorectal cancer: role of CT colonography in preoperative evaluation after incomplete colonoscopy. Radiology (2002) 1.32
Induction of hepatocellular carcinoma by in vivo gene targeting. Proc Natl Acad Sci U S A (2012) 1.31
Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol (2008) 1.26
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol (2012) 1.26
Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology (2013) 1.26
Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol (2011) 1.26
Treatment of hepatocellular carcinoma: is there an optimal strategy? Cancer Treat Rev (2003) 1.25
Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology (2008) 1.21
Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol (2009) 1.17
Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT. Eur Radiol (2003) 1.15
Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol (2012) 1.14
Hepatitis B virus and hepatocellular carcinoma. J Hepatol (2003) 1.14
HCC surveillance: who is the target population? Hepatology (2003) 1.12
Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology (2011) 1.07
Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin Cancer Res (2012) 1.05
Thermal ablation of hepatocellular carcinoma. Cancer Imaging (2008) 1.03
Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis (2010) 1.01
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol (2012) 1.01
Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging (2010) 1.00
Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. Liver Transpl (2003) 0.98
Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma. Hepatology (2014) 0.97
Benign regenerative nodules in Budd-Chiari syndrome and other vascular disorders of the liver: radiologic-pathologic and clinical correlation. Radiographics (2002) 0.95
Ethanol ablation of hepatocellular carcinoma Up to 5.0 cm by using a multipronged injection needle with high-dose strategy. Radiology (2009) 0.94
Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling. Semin Liver Dis (2006) 0.94
Two decades of advances in hepatocellular carcinoma research. Semin Liver Dis (2010) 0.94
Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. Eur J Gastroenterol Hepatol (2013) 0.93
Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol (2007) 0.93
Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link. Cancer Cell (2010) 0.92
Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled study. Hepatogastroenterology (2004) 0.92
Preoperative evaluation of biliary anatomy in adult live liver donors with volumetric mangafodipir trisodium enhanced magnetic resonance cholangiography. Liver Transpl (2004) 0.91
Large regenerative nodules in Budd-Chiari syndrome and other vascular disorders of the liver: CT and MR imaging findings with clinicopathologic correlation. AJR Am J Roentgenol (2002) 0.91
Prognostic assessment and evaluation of the benefits of treatment. J Clin Gastroenterol (2002) 0.90
Thermal ablation of lung tissue: in vivo experimental comparison of microwave and radiofrequency. Cardiovasc Intervent Radiol (2010) 0.89
Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology (2012) 0.88
Radiofrequency ablation of pulmonary tumors. Eur J Radiol (2010) 0.88